Leiden Jeffrey M's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Jul 27, 2022
- Accession no.
- 0000899243-22-026840
- Filed
- Jul 27, 2022
- Trade date
- Jul 25, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $37.2M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leiden Jeffrey MCIK 0001242825 | Director, Officer (Executive Chairman) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 25, 2022 | Common Stock | MOption exerciseAcquired | +60,342 | $91.05 | +$5,494,139.1 | 134,502 | Direct | |
| Jul 25, 2022 | Common Stock | SSaleDisposed | −13,869 | $279.44F2,F3 | −$3,875,553.36 | 120,633 | Direct | |
| Jul 25, 2022 | Common Stock | SSaleDisposed | −32,983 | $280.37F2,F4 | −$9,247,443.71 | 87,650 | Direct | |
| Jul 25, 2022 | Common Stock | SSaleDisposed | −34,090 | $281.27F2,F5 | −$9,588,494.3 | 53,560 | Direct | |
| Jul 25, 2022 | Common Stock | SSaleDisposed | −40,666 | $282.43F2,F6 | −$11,485,298.38 | 12,894 | Direct | |
| Jul 25, 2022 | Common Stock | SSaleDisposed | −10,471 | $283.42F2,F7 | −$2,967,690.82 | 2,423 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 25, 2022 | Common Stock | MOption exerciseDisposed | −60,342 | $0.00 | $0 | 33,524 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 5 transactions in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $279.44 (range $278.90 to $279.89).
Referenced by the price of 1 transaction in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $280.37 (range $279.90 to $280.88).
Referenced by the price of 1 transaction in Table I.
- F5
Open market sales reported on this line occurred at a weighted average price of $281.27 (range $280.90 to $281.89).
Referenced by the price of 1 transaction in Table I.
- F6
Open market sales reported on this line occurred at a weighted average price of $282.43 (range $281.90 to $282.89).
Referenced by the price of 1 transaction in Table I.
- F7
Open market sales reported on this line occurred at a weighted average price of $283.42 (range $282.90 to $283.84).
Referenced by the price of 1 transaction in Table I.